QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
NASDAQ:CING

Cingulate (CING) Stock Price, News & Analysis

$0.88
+0.03 (+3.31%)
(As of 03:49 PM ET)
Today's Range
$0.85
$0.90
50-Day Range
$0.79
$1.35
52-Week Range
$0.75
$23.80
Volume
43,767 shs
Average Volume
325,679 shs
Market Capitalization
$4.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Cingulate MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
830.1% Upside
$8.00 Price Target
Short Interest
Healthy
1.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.26mentions of Cingulate in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$1,490 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.28 out of 5 stars

CING stock logo

About Cingulate Stock (NASDAQ:CING)

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

CING Stock Price History

CING Stock News Headlines

This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Your Next Portfolio Star: Revealing 2024's Top Stock Pick
We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)
Why you can't focus and what science says can help
Cingulate to Attend DCAT Week 2024 in New York City
See More Headlines
Receive CING Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/18/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CING
Fax
N/A
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$8.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+815.3%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-23,530,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($5.88) per share

Miscellaneous

Free Float
3,085,000
Market Cap
$4.38 million
Optionable
Not Optionable
Beta
-0.95
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Shane J. Schaffer Pharm.D. (Age 48)
    PharmD, CEO, Principal Financial Officer & Chairman of the Board
    Comp: $491.96k
  • Dr. Laurie A. Myers M.B.A. (Age 66)
    Ph.D., Executive VP & COO
    Comp: $415.17k
  • Dr. Matthew N. Brams M.D. (Age 59)
    Executive VP & Chief Medical Officer
    Comp: $244.79k
  • Ms. Jennifer L. Callahan CPA (Age 53)
    CFO, Senior VP & Corporate Controller
  • Dr. Raul R. Silva M.D. (Age 65)
    Executive VP & Chief Science Officer
  • Thomas Dalton
    Head of Investor & Public Relations

CING Stock Analysis - Frequently Asked Questions

Should I buy or sell Cingulate stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cingulate in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CING shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CING, but not buy additional shares or sell existing shares.
View CING analyst ratings
or view top-rated stocks.

What is Cingulate's stock price target for 2024?

3 Wall Street research analysts have issued twelve-month target prices for Cingulate's stock. Their CING share price targets range from $8.00 to $8.00. On average, they expect the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 830.1% from the stock's current price.
View analysts price targets for CING
or view top-rated stocks among Wall Street analysts.

How have CING shares performed in 2024?

Cingulate's stock was trading at $7.65 at the start of the year. Since then, CING stock has decreased by 88.8% and is now trading at $0.8601.
View the best growth stocks for 2024 here
.

When is Cingulate's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our CING earnings forecast
.

When did Cingulate's stock split?

Cingulate shares reverse split before market open on Thursday, November 30th 2023. The 1-20 reverse split was announced on Thursday, November 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Cingulate IPO?

Cingulate (CING) raised $29 million in an initial public offering on Wednesday, December 8th 2021. The company issued 4,166,666 shares at $6.00-$8.00 per share.

How do I buy shares of Cingulate?

Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CING) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners